• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMJ Open . Cytokines and their relationship with the severity and prognosis of coronavirus disease 2019 (COVID-19): a retrospective cohort study

tetano

Editor, Senior Moderator
BMJ Open


. 2020 Nov 30;10(11):e041471.
doi: 10.1136/bmjopen-2020-041471.
Cytokines and their relationship with the severity and prognosis of coronavirus disease 2019 (COVID-19): a retrospective cohort study


Qing Quan Liu[SUP] #[/SUP][SUP] 1 [/SUP], Anying Cheng[SUP] #[/SUP][SUP] 1 [/SUP], Yiru Wang[SUP] 1 [/SUP], Haifang Li[SUP] 2 [/SUP], Liu Hu[SUP] 3 [/SUP], Xuecheng Zhao[SUP] 3 [/SUP], Tao Wang[SUP] 4 [/SUP], Fan He[SUP] 5 [/SUP]



Affiliations

Abstract

Objective: To delineate the characteristics and clinical significance of plasma inflammatory cytokines altered in COVID-19.
Design: Retrospective, single-centre cohort study.
Setting: Tongji Hospital in Wuhan, China.
Participants: Among a cohort of 308 patients with a diagnosis of COVID-19, 138 patients died while 170 patients recovered and were discharged from the hospital. The data were collected until 27 February 2020.
Primary and secondary outcome measures: Clinical characteristics and laboratory findings were obtained from electronic medical records using data collection forms.
Results: The percentage of patients with elevated interleukin 2 receptor (IL-2R), IL-6, IL-8, IL-10 and tumour necrosis factor (TNF) increased with severity of disease (p<0.0001 for all). IL-2R (p<0.0001), IL-6 (p<0.0001), IL-8 (p=0.0001), IL-10 (p<0.0001) and TNF (p<0.0001) were also twofold to 20-fold higher in patients who died compared with those who recovered. Also, IL-6 and IL-10 increased in both the progressive patient groups: moderate (p=0.0026) and severe (p<0.0001). In multivariate analysis, higher levels of IL-2R (OR 1.001, 95% CI 1.000 to 1.002, p=0.031) and IL-6 (OR 1.013, 95% CI 1.003 to 1.024, p=0.015) on admission were associated with increasing odds of in-hospital death, independent of other covariates, including severity of disease and lymphocyte count.
Conclusion: Increased proinflammatory and anti-inflammatory cytokines, including IL-2R, IL-6, IL-8, TNF and IL-10, showed an obvious association with both COVID-19 severity and in-hospital mortality. Thus, our study indicates that cytokines are valuable in predicting the severity of COVID-19 and helps in distinguishing critically ill patients from the less affected ones.

Keywords: COVID-19; immunology; infection control; respiratory infections.
 
Back
Top Bottom